---
title: "JAZZ: Record 2Q26 revenues up 16% YoY; guidance raised amid strong product and pipeline momentum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294732890.md"
description: "Record quarterly revenues of $1.2 billion marked a 16% YoY increase, with strong growth in Xywav, Epidiolex, and Zepzelca. Full-year 2026 revenue guidance was raised, and the company is positioned for new product launches and continued pipeline expansion.Original document: Jazz Pharmaceuticals plc [JAZZ] SEC 8-K Current Report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-03T20:12:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294732890.md)
  - [en](https://longbridge.com/en/news/294732890.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294732890.md)
generator: "portal-rs"
---

# JAZZ: Record 2Q26 revenues up 16% YoY; guidance raised amid strong product and pipeline momentum

Record quarterly revenues of $1.2 billion marked a 16% YoY increase, with strong growth in Xywav, Epidiolex, and Zepzelca. Full-year 2026 revenue guidance was raised, and the company is positioned for new product launches and continued pipeline expansion.

Original document: Jazz Pharmaceuticals plc \[JAZZ\] SEC 8-K Current Report — Aug. 3 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

- [Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032](https://longbridge.com/en/news/297565380.md)
- [Jazz Pharmaceuticals prices upsized USD 1.1 billion exchangeable senior notes offering due 2032](https://longbridge.com/en/news/297122954.md)
- [SPN: Q2 2026 saw record revenue growth, positive EBITDA, and improved margins amid ongoing macro headwinds](https://longbridge.com/en/news/297256815.md)
- [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md)
- [Jazz Pharma EVP Global Head of R&D and CMO Robert Iannone disposes of shares worth $19.23 million](https://longbridge.com/en/news/297568088.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**